Page 50 - Sohini Das

Manipal Health Enterprises set to buy AMRI Hospitals for Rs 2.3K crore

Temasek will buy controlling stake in Manipal at $4-billion valuation

India working on single-window portal for drug regulation processes

System will bring together stakeholders like manufacturers, distributors, state-run agencies to ensure quality

Uncertainty in Nigeria affects Indian auto, pharma, and consumer firms

Nigeria is a major destination for Indian pharmaceutical companies, especially mid-sized ones

Online pharmacies suffer without regulatory prescriptions in India

The absence of a legal framework governing this fast-growing segment of the pharma retailing business is causing confusion in the industry

Persistent chip, logistics woes frustrate car delivery timelines

Open order books in Feb breach 700K; wait period for some models exceed a year

In the fast lane: At 335,269 units, car sales create a February record

At the retail level, too, the industry posted 9.6 per cent YoY growth

Dr Reddy's acquires Mayne Pharma's USA prescription portfolio for $105 mn

The acquisition will complement DRL's US retail prescription pharmaceutical business with limited competition products

Centre forms panel to prepare road map for health care regulations

The committee will present a road map within the next one month

Chintan shivir on drugs to diagnose and treat issues of trust, quality

Proposals to be discussed at Hyderabad conclave include having a centralised drug registration system under CDSCO

Maruti Suzuki's rural market sales racing to reach the urban mark

Maruti Suzuki says proudly that they have helped to sell at least one car in 4.18 lakh villages

Maruti will have six EVs by 2030, working to bring down battery costs

Senior exec says cost of acquisition is a key factor impeding EV adoption in India

No link between use of ranitidine and cancer risk: Nature study

Ranitidine has been in existence for over four decades and has been on the WHO list of essential medicines for several years

Former Ranbaxy, DRL exec Rajeev Raghuvanshi appointed as new DCGI

Appointment comes at a time when India's pharma regulatory landscape is under the scanner

Two-wheeler electric vehicle sales may fall short of 1-million target

Still FY23 sales figure, so far, is up 146%; FY24 outlook is bright, say experts

Rajan Amba to take over as JLR managing director, succeeds Rohit Suri

Appointment comes at a time when JLR is facing supply chain issues hampering its production

Diagnostics sector looks to raise prices with new entrants revising rates

Online players had kept rates low, but with Covid time volumes gone, the trend is changing

Indian pharma R&D spends stay stagnant three years after pandemic downturn

Spends are now lower relative to sales than before Covid-19, stand at 4.4% of net sales, compared with 20% in the US

With 33% market share, Maruti eyes top slot in SUV space by FY24

At the moment, Tata Motors, Hyundai Motors India and Mahindra and Mahindra lead the SUV market

Have to keep R&D spends at 12% of revenue: Biocon's Kiran Mazumdar-Shaw

It's a high growth phase for us in Biocon Biologics: We crossed the Rs 1,500-crore mark in revenue for the first time this quarter. We will exit this year (FY23) at Rs 2,000-crore level

Viatris deal-related expenses drag Biocon's Q3 net into Rs 42 cr loss

This, even as revenues rise 36% and Ebitda is up 35%